Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing.

Kleinstiver BP, Sousa AA, Walton RT, Tak YE, Hsu JY, Clement K, Welch MM, Horng JE, Malagon-Lopez J, Scarfò I, Maus MV, Pinello L, Aryee MJ, Joung JK.

Nat Biotechnol. 2019 Feb 11. doi: 10.1038/s41587-018-0011-0. [Epub ahead of print]

PMID:
30742127
2.

Discovery of widespread type I and type V CRISPR-Cas inhibitors.

Marino ND, Zhang JY, Borges AL, Sousa AA, Leon LM, Rauch BJ, Walton RT, Berry JD, Joung JK, Kleinstiver BP, Bondy-Denomy J.

Science. 2018 Oct 12;362(6411):240-242. doi: 10.1126/science.aau5174. Epub 2018 Sep 6.

PMID:
30190308
3.

Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs.

Listgarten J, Weinstein M, Kleinstiver BP, Sousa AA, Joung JK, Crawford J, Gao K, Hoang L, Elibol M, Doench JG, Fusi N.

Nat Biomed Eng. 2018 Jan;2(1):38-47. doi: 10.1038/s41551-017-0178-6. Epub 2018 Jan 10.

4.

Activities and specificities of CRISPR/Cas9 and Cas12a nucleases for targeted mutagenesis in maize.

Lee K, Zhang Y, Kleinstiver BP, Guo JA, Aryee MJ, Miller J, Malzahn A, Zarecor S, Lawrence-Dill CJ, Joung JK, Qi Y, Wang K.

Plant Biotechnol J. 2019 Feb;17(2):362-372. doi: 10.1111/pbi.12982. Epub 2018 Jul 22.

5.

CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease.

György B, Lööv C, Zaborowski MP, Takeda S, Kleinstiver BP, Commins C, Kastanenka K, Mu D, Volak A, Giedraitis V, Lannfelt L, Maguire CA, Joung JK, Hyman BT, Breakefield XO, Ingelsson M.

Mol Ther Nucleic Acids. 2018 Jun 1;11:429-440. doi: 10.1016/j.omtn.2018.03.007. Epub 2018 Mar 16.

6.

Temporal and Spatial Post-Transcriptional Regulation of Zebrafish tie1 mRNA by Long Noncoding RNA During Brain Vascular Assembly.

Chowdhury TA, Koceja C, Eisa-Beygi S, Kleinstiver BP, Kumar SN, Lin CW, Li K, Prabhudesai S, Joung JK, Ramchandran R.

Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1562-1575. doi: 10.1161/ATVBAHA.118.310848. Epub 2018 May 3.

7.

Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors.

Tak YE, Kleinstiver BP, Nuñez JK, Hsu JY, Horng JE, Gong J, Weissman JS, Joung JK.

Nat Methods. 2017 Dec;14(12):1163-1166. doi: 10.1038/nmeth.4483. Epub 2017 Oct 30.

8.

Enhanced proofreading governs CRISPR-Cas9 targeting accuracy.

Chen JS, Dagdas YS, Kleinstiver BP, Welch MM, Sousa AA, Harrington LB, Sternberg SH, Joung JK, Yildiz A, Doudna JA.

Nature. 2017 Oct 19;550(7676):407-410. doi: 10.1038/nature24268. Epub 2017 Sep 20.

9.

Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.

Ando K, Shah AK, Sachdev V, Kleinstiver BP, Taylor-Parker J, Welch MM, Hu Y, Salgia R, White FM, Parvin JD, Ozonoff A, Rameh LE, Joung JK, Bharti AK.

Oncotarget. 2017 Jul 4;8(27):43733-43751. doi: 10.18632/oncotarget.16376.

10.

Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells.

Kleinstiver BP, Tsai SQ, Prew MS, Nguyen NT, Welch MM, Lopez JM, McCaw ZR, Aryee MJ, Joung JK.

Nat Biotechnol. 2016 Aug;34(8):869-74. doi: 10.1038/nbt.3620. Epub 2016 Jun 27.

11.

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.

Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N.

Cancer Discov. 2016 Jul;6(7):727-39. doi: 10.1158/2159-8290.CD-15-1442. Epub 2016 May 26.

12.

High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK.

Nature. 2016 Jan 28;529(7587):490-5. doi: 10.1038/nature16526. Epub 2016 Jan 6.

13.

Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition.

Kleinstiver BP, Prew MS, Tsai SQ, Nguyen NT, Topkar VV, Zheng Z, Joung JK.

Nat Biotechnol. 2015 Dec;33(12):1293-1298. doi: 10.1038/nbt.3404. Epub 2015 Nov 2.

14.

Engineered CRISPR-Cas9 nucleases with altered PAM specificities.

Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, Gonzales AP, Li Z, Peterson RT, Yeh JR, Aryee MJ, Joung JK.

Nature. 2015 Jul 23;523(7561):481-5. doi: 10.1038/nature14592. Epub 2015 Jun 22.

15.

Hypoxia drives transient site-specific copy gain and drug-resistant gene expression.

Black JC, Atabakhsh E, Kim J, Biette KM, Van Rechem C, Ladd B, Burrowes PD, Donado C, Mattoo H, Kleinstiver BP, Song B, Andriani G, Joung JK, Iliopoulos O, Montagna C, Pillai S, Getz G, Whetstine JR.

Genes Dev. 2015 May 15;29(10):1018-31. doi: 10.1101/gad.259796.115.

16.

The I-TevI nuclease and linker domains contribute to the specificity of monomeric TALENs.

Kleinstiver BP, Wang L, Wolfs JM, Kolaczyk T, McDowell B, Wang X, Schild-Poulter C, Bogdanove AJ, Edgell DR.

G3 (Bethesda). 2014 Apr 16;4(6):1155-65. doi: 10.1534/g3.114.011445.

17.

Rapid screening of endonuclease target site preference using a modified bacterial two-plasmid selection.

Wolfs JM, Kleinstiver BP, Edgell DR.

Methods Mol Biol. 2014;1123:97-104. doi: 10.1007/978-1-62703-968-0_8.

PMID:
24510263
18.

The monomeric GIY-YIG homing endonuclease I-BmoI uses a molecular anchor and a flexible tether to sequentially nick DNA.

Kleinstiver BP, Wolfs JM, Edgell DR.

Nucleic Acids Res. 2013 May 1;41(10):5413-27. doi: 10.1093/nar/gkt186. Epub 2013 Apr 4.

19.

Monomeric site-specific nucleases for genome editing.

Kleinstiver BP, Wolfs JM, Kolaczyk T, Roberts AK, Hu SX, Edgell DR.

Proc Natl Acad Sci U S A. 2012 May 22;109(21):8061-6. doi: 10.1073/pnas.1117984109. Epub 2012 May 7.

20.

Divalent metal ion differentially regulates the sequential nicking reactions of the GIY-YIG homing endonuclease I-BmoI.

Kleinstiver BP, Bérubé-Janzen W, Fernandes AD, Edgell DR.

PLoS One. 2011;6(8):e23804. doi: 10.1371/journal.pone.0023804. Epub 2011 Aug 22.

Supplemental Content

Loading ...
Support Center